n-methylisoindigotin has been researched along with Granulocytic Leukemia, Chronic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, F; Hou, M; Ji, C; Li, L; Ma, D; Sun, J; Yan, S; Zhang, M | 1 |
| Hao, Y; Liu, B; Qian, L; Xiao, Z | 2 |
| Han, Z; Hao, Y; Li, Z; Lu, L; Peng, Z; Wang, Y; Xiao, Z | 1 |
1 review(s) available for n-methylisoindigotin and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Blast Crisis; China; Dose-Response Relationship, Drug; Humans; Hydroxyurea; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Chemical; Time Factors; Treatment Outcome | 2002 |
3 other study(ies) available for n-methylisoindigotin and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.
Topics: Adult; Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction | 2010 |
Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro.
Topics: Angiogenesis Inhibitors; Apoptosis; Cell Adhesion; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Indoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neovascularization, Physiologic; Vascular Endothelial Growth Factor A | 2006 |
Meisoindigo for the treatment of chronic myelogenous leukaemia.
Topics: Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Hydroxyurea; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nucleic Acid Synthesis Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies | 2000 |